Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 14, 2005

Primary Completion Date

February 11, 2010

Study Completion Date

March 19, 2026

Conditions
Gastrointestinal Stromal Tumor
Interventions
DRUG

Sorafenib Tosylate

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

60637

University of Chicago Comprehensive Cancer Center, Chicago

62526

Decatur Memorial Hospital, Decatur

62702

Central Illinois Hematology Oncology Center, Springfield

91010

City of Hope Comprehensive Cancer Center, Duarte

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH